Vandortuzumab
Based on 1 Customer Validation
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.00%
- 分子量:145.5 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-P99001
Human IgG1 kappa, Isotype ControlIgG1κ Isotype Control -
HY-P990688
XaluritamigT-cell Activator -
HY-P991503
Anti-STEAP2 AntibodySTEAP2 Antibody -
HY-P99239
RosopatamabHumanized Anti-PSMA mAb -
HY-P99045
SacituzumabAnti-TROP-2 Antibody -
HY-A0070A
LiothyronineTIGIT/PVR Blocker -
HY-P9905
CetuximabEGFR Inhibitor -
HY-P9966
EnoblituzumabB7-H3 mAb -
HY-P99201
ZilovertamabROR1 Inhibitor -
HY-P99192
EmibetuzumabBivalent MET Antibody -
HY-P990608
AlpitatugVEGFR3 Inhibitor -
HY-P99206
NaxitamabGD2 Inhibitor
生物活性
製品説明
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
STEAP1
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa
アプリケーション
ELISA, FACS, Functional assay
化学情報
-
性状 Liquid
-
分子量 145.5 kDa
-
Color Colorless to light yellow
-
別名
DSTP-3086S Antibody; RG-7450 Antibody
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Alberti C. Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance. G Chir. 2017 Sep-Oct;37(5):225-235. [Content Brief]
[3]. Danila DC, et al. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019;37(36):3518-3527. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Vandortuzumab 関連分類
HY-P990673 関連分類
Powered by Bioz